Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $925 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a $925 price target.

May 03, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald reaffirmed a Neutral rating on Regeneron Pharmaceuticals with a $925 price target.
The reiteration of a Neutral rating and maintenance of the price target by a significant analyst firm like Cantor Fitzgerald suggests no immediate positive or negative catalysts for Regeneron Pharmaceuticals. This stance likely indicates that the analyst views the stock as fairly valued at its current level, with the $925 price target suggesting a neutral outlook on the stock's short-term price movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90